Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 microg Ethinylestradiol and 100 microg Levonorgestrel in a 21-Day Regimen for 7 Cycles in 400 Women.

Trial Profile

Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 microg Ethinylestradiol and 100 microg Levonorgestrel in a 21-Day Regimen for 7 Cycles in 400 Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2014

At a glance

  • Drugs Ethinylestradiol/gestodene (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy
  • Focus Pharmacodynamics; Registrational
  • Sponsors Bayer
  • Most Recent Events

    • 28 Jan 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2010 Actual patient number changed from 254 to 307 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top